ADMA stock forecast
Our latest prediction for ADMA Biologics, Inc.'s stock price was made on the June 6, 2019 when the stock price was at 3.77$.
In the short term (2weeks), ADMA's stock price should underperform the market by -0.15%. During that period the price should oscillate between -11.76% and +15.17%.
In the medium term (3months), ADMA's stock price should underperform the market by -0.75%. During that period the price should oscillate between -24.70% and +38.82%.Get email alerts
About ADMA Biologics, Inc.
ADMA Biologics, Inc. operates as a biopharmaceutical company. It develops, manufactures, and intends to commercialize in human plasma and plasma-derived therapeutics. The firm operates through the following business segments: ADMA BioManufacturing, Plasma Collection Center, and Corporate. The ADMA BioManufacturing segment comprises of the immune globulin manufacturing and development operations. The Plasma Collection Center consists of source plasma collection facilities. The Corporate segment includes general and administrative overhead expenses. The company was founded by Adam S. Grossman and Jerrold B. Grossman on June 2, 2006 and is headquartered in Hackensack, NJ.
At the moment the company generates 21M USD in revenues.
On its last earning announcement, the company reported a loss of -1.11$ per share.
The book value per share is 1.12$
Three months stock forecastJune 6, 2019
|Revenue USD||Gross Margin||Operating Income||Operating Margin||Net Income||Earnings Per Share||Dividends||Payout Ratio||Shares||Book Value Per Share||Operating Cash Flow||Cap Spending||Free Cash Flow|